Compass Pathways is a brand-new company record, and its full research profile isn't ready yet.
compasspathways.comCrawled Oct 25, 2026
Compass Pathways outlines its policy on expanded access and compassionate use requests for its investigational treatment, including eligibility criteria and application details.
Compass Pathways develops psychedelic treatments for difficult-to-treat mental health conditions, backed by clinical science for US clinicians.
A decade of rigorous clinical research. 1,450+ trial participants, 14 trials, 125+ research sites across 13 countries—advancing new options in mental health.
Your treatments failed you—not the other way around. Advancing new options for difficult-to-treat mental health conditions.
The page lists peer-reviewed papers supporting Compass Pathways’ clinical research in difficult-to-treat mental health conditions.
Dr. Guy Goodwin is an Oxford-trained psychiatrist, former ECNP President, and top-cited researcher leading clinical development at Compass Pathways.
Dr. Michael Gold, CRDO at Compass Pathways, is a neurologist and 30-year drug development leader, formerly VP Neurosciences at AbbVie and CMO at Neumora.
Kabir Nath, CEO of Compass Pathways, brings 30 years of global biopharma leadership, previously leading Otsuka's North America and global businesses.
Kelly Boucher, CPO at Compass Pathways, brings a distinctive approach to people leadership that sits at the intersection of culture, science and strategy.
Finders inspired by seekers. Compass Pathways is driven by commitment to patients, rigorous science, and a future full of new possibilities.
Compass Pathways was founded to address gaps between patient needs and available medical treatments.
The page answers questions about Compass Pathways, its clinical program, and its implications for patients, caregivers, healthcare professionals, and investors.
Every journey needs a Compass. Advancing new options for people living with difficult-to-treat mental health conditions through rigorous science and compassion.